This site is intended for Healthcare professionals only.

Spurious Drugs Issue: DCGI Invites Top Pharma Brands on 25th June

Spurious Drugs Issue: DCGI Invites Top Pharma Brands on 25th June

New Delhi: Through a recent notification, the Drug Controller General of India has invited manufacturers for a meeting on the introduction of trace and track for the top pharmaceuticals brands on 25th June 2018.

The Central Drugs Standard Control Organisation (CDSCO), Office of Drugs Controller General (I), Directorate General of Health services has taken another step forward in order to introduce an effective “trace and track” mechanism to curb the nuisance of spurious drugs from the Indian market.

The national drug regulatory body has identified the top 300 brands, which would be included in the initiative, on the basis of moving annual total (MAT) data provided by AIOCD AWACS and will hold a meeting with manufacturers’ representatives on June 25 to discuss modalities for implementing the initiative.

The Drugs Technical Advisory Board in its 79th meeting held on 16.5.2018 considered the proposal for the introduction of trace and track for the most popular or top 300 pharmaceutical brands available in the Indian market on trial basis.

The Board recommended for the introduction of trace and track mechanism for top 300 pharmaceutical brands and stated that Drugs Controller General (I) may issue an order to this effect. Accordingly, the top 300 brands have been identified based on the MAT data provided by AIOCD AWACS.

Read also: Trace And Track: DTAB approves proposal to track 300 pharmaceutical brands

Dr. S. Eswara Reddy, DCGI will chair a meeting on 25.6.2018 at 3.00 PM at 5th floor, FDA Bhawan, New Delhi to discuss the modalities for implementing the DTAB decision. The firms mentioned in the address entry are requested to make it convenient to attend the meeting and share your views in this regard.

The list of manufacturers includes Abbot India with 13 brands, Cipla Limited with 17, Sun Pharma with 22 brands and Pfizer Limited with 15 products.

Below is the attachment for the same

Source: self
1 comment(s) on Spurious Drugs Issue: DCGI Invites Top Pharma Brands on 25th June

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted
  1. DCGI must have some system of third party validation of drug quality being manufactured. It is strange that daily use items have ISI certification but drugs do not. Drugs should have three levels of standardisation: 1. Manufacture as per Indian phharmacopea2. Certification by the company regarding quality and strength of drug.3. Third party validation by government labs for all drugs released in the market